Jan. 9 at 12:09 PM
$CATX With longer follow-up and a growing body of clinical experience, we continue to see evidence of sustained and deepening anti-tumor activity for VMT-α-NET at the dose level evaluated in Cohort 2, while the favorable tolerability profile is maintained, possibly even at a higher dose," said Vikas Prasad, MD, Professor of Radiology, Mallinckrodt Institute of Radiology, Siteman Cancer Center, Washington University School of Medicine. "These data further support continued dose optimization, and I look forward to discussing the evolving results with the gastrointestinal oncology community as this study progresses."
